MANJINDER KAUR: Open Payments
NPI 1073170973 · PARAMUS, NJ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$684 in 15 payments from 6 companies in 2025. Trend: 2023 $126 · 2024 $287 · 2025 $684
Food & beverage: $684
| Company | Payments | Amount |
|---|---|---|
| GlaxoSmithKline, LLC. | 7 | $207 |
| ABBVIE INC. | 1 | $128 |
| Novo Nordisk Inc | 1 | $125 |
| Gilead Sciences, Inc. | 1 | $125 |
| ARS Pharmaceuticals Operations, Inc. | 3 | $60 |
| Lilly USA, LLC | 2 | $38 |
Products named: NUCALA, BOTOX, Ozempic, Biktarvy, NEFFY, ZEPBOUND, TRELEGY ELLIPTA.
Industry payments across NJ — which companies pay providers there.
